Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 8/20 | 0.55 |
| ▸ | DRD3 | P35462 | 8/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | TERT | O14746 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511121 | 0.86 | DRD2 (0.58) | ACHEDRD2DRD3HTR1AHTR2A | |
| SCHEMBL13033512 | 0.85 | ACHE (0.76) | ACHEDRD2DRD3HTR1AHTR2A | |
| SCHEMBL13033493 | 0.83 | DRD2 (0.61) | ACHEDRD2DRD3HTR1AHTR2A | |
| SCHEMBL13033508 | 0.83 | ACHE (0.58) | ACHEDRD2DRD3HTR1AHTR2A | |
| SCHEMBL3510972 | 0.82 | ACHE (0.51) | ACHEDRD2DRD3HTR1AHTR2A | |
| SCHEMBL13033513 | 0.81 | ACHE (0.56) | ACHEDRD2DRD3HTR1AHTR2A | |
| SCHEMBL7637232 | 0.81 | SMN1; SMN2 (0.58) | ACHEDRD2DRD3HTR1AHTR2A | |
| SCHEMBL3511927 | 0.81 | ACHE (0.53) | ACHEDRD2DRD3HTR1AHTR2A | |
| SCHEMBL13033488 | 0.81 | LMNA (0.51) | ACHEDRD2DRD3DRD4KDM4E | |
| SCHEMBL3510803 | 0.79 | ACHE (0.48) | ACHEDRD2DRD3HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | ACHE 4747/4885DRD2 4279/4885DRD3 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.